Screener
Vertex Pharmaceuticals VRTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's total liabilities?
- Vertex Pharmaceuticals (VRTX) reported total liabilities of $7.12B in Q1 2026.
- How has Vertex Pharmaceuticals's total liabilities changed year-over-year?
- Vertex Pharmaceuticals's total liabilities increased by 11.6% year-over-year, from $6.38B to $7.12B.
- What is the long-term trend for Vertex Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total liabilities has grown at a 17.9% compound annual growth rate (CAGR), from $3.07B to $6.98B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Vertex Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude